| Item Type | Name |
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
|
Concept
|
Vascular Endothelial Growth Factor Receptor-3
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Vascular Endothelial Growth Factor C
|
|
Concept
|
Vascular Endothelial Growth Factor Receptor-1
|
|
Academic Article
|
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
|
|
Academic Article
|
Targeted agents for the treatment of advanced renal cell carcinoma.
|
|
Academic Article
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
|
|
Academic Article
|
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
|
|
Academic Article
|
Sorafenib.
|
|
Academic Article
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
|
Academic Article
|
New targets, therapies, and toxicities: lessons to be learned.
|
|
Academic Article
|
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
|
|
Academic Article
|
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
|
|
Academic Article
|
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
|
|
Academic Article
|
Bevacizumab and everolimus in renal cancer: a rational way forward.
|
|
Academic Article
|
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
|
|
Academic Article
|
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
|
|
Academic Article
|
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
|
|
Academic Article
|
Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer.
|
|
Academic Article
|
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
|
|
Academic Article
|
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
|
|
Academic Article
|
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
|
|
Academic Article
|
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
|
|
Academic Article
|
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
|